JLE

Hépato-Gastro & Oncologie Digestive

MENU

Résultats et perspectives de la radioembolisation du carcinome hépatocellulaire Volume 26, numéro 9, Novembre 2019

  • [1] Louie J.D., Kothary N., Kuo W.T. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol. 2009;20:606-613.
  • [2] van den Hoven A.F., Prince J.F., de Keizer B. Use of C-Arm Cone Beam CT During Hepatic Radioembolization : Protocol Optimization for Extrahepatic Shunting and Parenchymal Enhancement. Cardiovasc Intervent Radiol. 2016;39:64-73.
  • [3] Kallini J.R., Gabr A., Salem R. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther. 2016;33:699-714.
  • [4] Lewandowski R.J., Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23:64-72.
  • [5] Vilgrain V., Abdel-Rehim M., Sibert A. Radioembolisation with yttrium90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH) : study protocol for a randomised controlled trial. Trials. 2014;15:474.
  • [6] Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB : Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018 ; 36 : 1913-1921.
  • [7] Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol 2017 ; 18 : 1624-1636.
  • [8] Sangro B., Carpanese L., Cianni R. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011;54:868-878.
  • [9] Salem R., Gabr A., Riaz A. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018;68:1429-1440.
  • [10] Salem R., Lewandowski R.J., Kulik L. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.
  • [11] Salem R., Gordon A.C., Mouli S. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155-1163.
  • [12] El Fouly A., Ertle J., El Dorry A. In intermediate stage hepatocellular carcinoma : radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35:627-635.
  • [13] Lewandowski R.J., Kulik L.M., Riaz A. A comparative analysis of transarterial downstaging for hepatocellular carcinoma : chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928.
  • [14] Abouchaleh N., Gabr A., Ali R. (90)Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis : Long-Term Outcomes in a 185-Patient Cohort. J Nucl Med. 2018;59:1042-1048.
  • [15] Golfieri R., Mosconi C., Cappelli A. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. Future Oncol. 2015;11:3133-3142.
  • [16] Gulec S.A., Pennington K., Hall M. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment : a novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:6.
  • [17] Lewandowski R.J., Donahue L., Chokechanachaisakul A. (90) Y radiation lobectomy : Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114:99-105.
  • [18] Vouche M., Habib A., Ward T.J. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation : multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192-201.
  • [19] Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation Segmentectomy : Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology 2018 ; 287 : 1050-1058.
  • [20] Johnson P.J., Berhane S., Kagebayashi C. Assessment of liver function in patients with hepatocellular carcinoma : a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550-558.
  • [21] Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 2010 ; 138 : 52-64.
  • [22] Niekamp A., Abdel-Wahab R., Kuban J. Baseline apparent diffusion coefficient as a predictor of response to liver-directed therapies in hepatocellular carcinoma. J Clin Med. 2018;7.
  • [23] Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018 ; 68 : 724-732.
  • [24] Blanc-Durand P., Van Der Gucht A., Jreige M. Signature of survival: A (18)F-FDG PET based whole-liver radiomic analysis predicts survival after (90)Y-TARE for hepatocellular carcinoma. Oncotarget. 2018;9:4549-4558.